Platform for humanized biological raw material production
With synthetic biology strategy, GEcoll performs sophisticate LS-Gene Editing in various organisms. By replacing endogenous genes with human genes, we enable animals and plants to produce humanized recombinant proteins.
GEcoll provides our clients safe, clean, reliable and traceable raw biomaterials with ISO-13485 standard. These high-quality biomaterials will be the keys for research and development of tissue engineering, regenerative medicine and 3D-printing organs.
GEcoll is currently developing rice-based platform for humanized Elastin, humanized growth factor and the SPF/medical grade rat-based platform for humanized collagen.
The platforms GEcoll developed for recombinant humanized protein production are in line with the trends of green science and animal welfare. Moreover, biomaterials produced by GEcoll’s platforms are free from contamination that commercially available animal-derived materials might have due to livestock diseases or environmental pollution.
GEcoll Biomedical focuses on the development of biosynthesis platforms and the production of humanized raw materials. It will be applied to medical aesthetics, articular cartilage repair and wound dressing. GEcoll aims to be an international company for humanized biomaterials development.